Nguyen Thi Mai Phuong1,2, Hua Thanh Thuy1, Ong The Due2, Phung Lam Toi2, Do Thi Thu Hien3, Nguyen Van Thanh3, Vuong Trong Hieu4, Pham Nu Hanh Van4
1.Hanoi University of Public health, 2. Health Strategy and Policy Institute, 3. National Hospital of Dermatology and Venereology, 4. Hanoi University of Pharmacy
Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. This study assessed the cost-effectiveness of secukinumab, an interleukin-17A inhibitor, versus standard of care (SoC) from Vietnam’s National Health Insurance (NHI) perspective.
Methods: Model-based cost-effectiveness analysis, the structure was a 3-month decision tree leading into a Markov model. Clinical parameters, including responses at 3 months, were from the FUTURE 2 trial. Cost parameters were from real data at the National Hospital of Dermatology and Venereology and a research period. The outcome included total costs and quality-adjusted life years (QALYs) over a life-time horizon (3.5% annual discount for both outcomes and cost), and incremental cost-effectiveness ratios (ICER). The robustness of the study findings was evaluated via sensitivity analysis.
Results: Patients treated with secukinumab achieved with QALY gain 1.16 versus SoC, but associated with higher total costs was 211.3 million VND over lifetime horizon. ICER for secukinumab vs SoC was 181.6 million VND lower than a willingness to pay threshold recommended in Vietnam (3GDP per capita equal to 286.8 million VND). Deterministic sensitivity analysis indicated that parameters related to Health Assessment Questionnaire scores were most influential. At the willingness to pay threshold of three times the GDPpc, the probability of secukinumab being cost-effective was 90.3% in the probabilistic sensitivity analysis.
Conclusions: Secukinumab is a cost-effectiveness treatment versus SoC for PsA patients from the National health insurance’s perspective of Vietnam.
Source: Journal of Pharmaceutical Research & Drug Information. Volume 14, Issue 5, pages 2 - 11. November 27th, 2023
DOI: https://doi.org/10.59882/1859-364X/122